Literature DB >> 23199951

Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases.

F Xavier Bosch1, Vivien Tsu, Alex Vorsters, Pierre Van Damme, Mark A Kane.   

Abstract

The reframed paradigm of cervical cancer prevention will include strategic combinations of at least four major components: 1) routine introduction of human papillomavirus (HPV) vaccines to women in all countries, 2) extension and simplification of existing screening programs using HPV-based technology, 3) extension of adapted screening programs to developing populations, and 4) consideration of the broader spectrum of cancers and other diseases preventable by HPV vaccination in women, as well as in men. On a global scale, vaccination of newborns and infants is well established and has developed a successful working infrastructure. The hepatitis B virus (HBV) vaccination programs offer a model for HPV introduction in which newborn and infant immunization achieves a rapid reduction in the prevalence of the HBV carrier rates in immunized cohorts of children, and of liver cirrhosis and liver cancer decades later. In contrast, screening for cervical pre-cancer is largely restricted to industrialized populations and upper social classes in developing countries. The expertise gained by vaccination programs worldwide needs to be coordinated with the traditional cervical cancer prevention community of gynecologists and pathologists. Significant political and advocacy efforts at the Global level (World Health Organization, other United Nations agencies and The GAVI Alliance) need to be organized and reinforced to achieve a meaningful reduction in HPV transmission and its related health conditions and cancers. This desirable goal is now scientifically and technologically attainable, and great progress is being made in obtaining financing for global HPV immunization. This article forms part of a special supplement entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23199951     DOI: 10.1016/j.vaccine.2012.05.090

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

Review 1.  Present challenges in cervical cancer prevention: Answers from cost-effectiveness analyses.

Authors:  Mireia Diaz; Silvia de Sanjosé; F Xavier Bosch; Laia Bruni
Journal:  Rep Pract Oncol Radiother       Date:  2018-04-26

2.  Parents' views on human papillomavirus vaccination for sexually transmissible infection prevention: a qualitative study.

Authors:  Linda M Niccolai; Caitlin E Hansen; Marisol Credle; Sheryl A Ryan; Eugene D Shapiro
Journal:  Sex Health       Date:  2014-07       Impact factor: 2.706

3.  Comprehensive control of human papillomavirus infections and related diseases.

Authors:  F Xavier Bosch; Thomas R Broker; David Forman; Anna-Barbara Moscicki; Maura L Gillison; John Doorbar; Peter L Stern; Margaret Stanley; Marc Arbyn; Mario Poljak; Jack Cuzick; Philip E Castle; John T Schiller; Lauri E Markowitz; William A Fisher; Karen Canfell; Lynette A Denny; Eduardo L Franco; Marc Steben; Mark A Kane; Mark Schiffman; Chris J L M Meijer; Rengaswamy Sankaranarayanan; Xavier Castellsagué; Jane J Kim; Maria Brotons; Laia Alemany; Ginesa Albero; Mireia Diaz; Silvia de Sanjosé
Journal:  Vaccine       Date:  2013-12-31       Impact factor: 3.641

Review 4.  Systematic review of model-based cervical screening evaluations.

Authors:  Diana Mendes; Iren Bains; Tazio Vanni; Mark Jit
Journal:  BMC Cancer       Date:  2015-05-01       Impact factor: 4.430

Review 5.  Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review.

Authors:  Luciano Mariani; Patrizia Vici; Barbara Suligoi; Giovanni Checcucci-Lisi; Rosybel Drury
Journal:  Adv Ther       Date:  2015-01-27       Impact factor: 3.845

6.  Characteristics of memory B cells elicited by a highly efficacious HPV vaccine in subjects with no pre-existing immunity.

Authors:  Erin M Scherer; Robin A Smith; Cassandra A Simonich; Nixon Niyonzima; Joseph J Carter; Denise A Galloway
Journal:  PLoS Pathog       Date:  2014-10-16       Impact factor: 6.823

7.  HPV Prevention series.

Authors:  Silvia de Sanjosé
Journal:  Infect Agent Cancer       Date:  2012-12-20       Impact factor: 2.965

8.  Ubiquitin B in cervical cancer: critical for the maintenance of cancer stem-like cell characters.

Authors:  Yuan Tian; Wencheng Ding; Yingying Wang; Teng Ji; Shujuan Sun; Qingqing Mo; Pingbo Chen; Yong Fang; Jia Liu; Beibei Wang; Jianfeng Zhou; Ding Ma; Peng Wu
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

9.  Not the right time: why parents refuse to let their daughters have the human papillomavirus vaccination.

Authors:  Maria Grandahl; Marie Oscarsson; Christina Stenhammar; Tryggve Nevéus; Ragnar Westerling; Tanja Tydén
Journal:  Acta Paediatr       Date:  2014-01-08       Impact factor: 2.299

Review 10.  Comprehensive control of human papillomavirus infections and related diseases.

Authors:  F Xavier Bosch; Thomas R Broker; David Forman; Anna-Barbara Moscicki; Maura L Gillison; John Doorbar; Peter L Stern; Margaret Stanley; Marc Arbyn; Mario Poljak; Jack Cuzick; Philip E Castle; John T Schiller; Lauri E Markowitz; William A Fisher; Karen Canfell; Lynette A Denny; Eduardo L Franco; Marc Steben; Mark A Kane; Mark Schiffman; Chris J L M Meijer; Rengaswamy Sankaranarayanan; Xavier Castellsagué; Jane J Kim; Maria Brotons; Laia Alemany; Ginesa Albero; Mireia Diaz; Silvia de Sanjosé
Journal:  Vaccine       Date:  2013-11-22       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.